Evidence-Based Pan-Hematopoietic NGS Gene Panel

Evidence-Based Pan-Hematopoietic NGS Gene Panel

Using Mastermind to automate the design of a pan-hematopoietic malignancy gene panel, Dr. Mark Kiel generated a set of biomarker candidates that includes 314 genes associated with leukemia and 311 genes associated with lymphoma. Each of these candidate biomarker genes were manually annotated based on likely mechanism of pathogenesis including mutation, expression, copy number and structural rearrangement.

Data supporting the prioritization of the genes includes the number of articles that cited  the disease-gene association as well as a breakdown of the number of these papers that suggest diagnostic, prognostic and therapeutic significance. The top ranking citations for each are also depicted in the final panel as are hyperlinks into the Mastermind software to permit further examination of this evidence.

The result is a highly comprehensive gene panel of over 300 genes with all associated variants supported by specific literature citations from thousands of research publications that is easily scalable for any disease or gene of interest.

List of Lymphoma Gene Panel Candidates
Comprehensive Lymphoma Gene Panel Candidate BioMarkers

A white paper on the design process for the pan-hematopoietic malignancy gene panel, the gene list and the supporting evidence is publicly available.

Download:  Pan-hematopoietic gene panel white paper here.

Contact us to request a spreadsheet of the supporting evidence including the list of genes and literature citations for each gene.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s